<SEC-DOCUMENT>0001171843-22-005963.txt : 20220906
<SEC-HEADER>0001171843-22-005963.hdr.sgml : 20220906
<ACCEPTANCE-DATETIME>20220906164512
ACCESSION NUMBER:		0001171843-22-005963
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220906
FILED AS OF DATE:		20220906
DATE AS OF CHANGE:		20220906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Profound Medical Corp.
		CENTRAL INDEX KEY:			0001628808
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39032
		FILM NUMBER:		221228774

	BUSINESS ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5
		BUSINESS PHONE:		647-476-1350

	MAIL ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Profound Medical Inc.
		DATE OF NAME CHANGE:	20141222
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_090622.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of September 2022</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39032</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>PROFOUND MEDICAL CORP. </strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 </strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;&#160; ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;X ]</p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): </p><p>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): </p><hr style="page-break-after: always;" noshade="noshade" /><p> <p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><p>The following document is attached as an exhibit hereto and is incorporated by reference herein: &#160;</p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline; text-align: center;" valign="bottom"><font style="font-size: 10pt;"><strong>Title</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;"><a href="exh_991.htm">Press Release dated September 6, 2022</a> </font></td></tr></table></p><p /><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURES</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;PROFOUND MEDICAL CORP. &#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: September 6, 2022</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Rashed Dewan&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Rashed Dewan</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Financial Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><html lang="en-US"><head><title>EdgarFiling</title><meta content="text/html; charset=windows-1252" ><meta name="GENERATOR" content="MSHTML 8.00.7601.18094" ></head><body bgcolor="#ffffff"><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><font style="font-size: 14pt;"><strong>Profound Medical to Participate in September Investor Conferences</strong></font></p><p style="text-align: center;"><strong></strong></p><p ></p>
 <p align="justify">TORONTO, Sept.  06, 2022  (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#8220;Profound&#8221; or the &#8220;Company&#8221;), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in September.<br ></p>  <ul type="disc"><li style="margin-bottom:12pt; text-align:justify;"><strong>Lake Street&#8217;s 6th Annual BIG Conference:</strong> Profound is scheduled to participate in a series of one-on-one meetings on Wednesday, September 14, 2022.</li><li style="margin-bottom:12pt; text-align:justify;"><strong>A.G.P.&#8217;s Virtual MedTech Conference:</strong> Profound is scheduled to participate in a series of one-on-one meetings on Wednesday, September 21, 2022.</li></ul>  <p align="justify">Due to the format of both events, no webcasts will be available.</p>  <p align="justify"><strong>About Profound Medical Corp.</strong></p>  <p align="justify">Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.</p>  <p align="justify">Profound is commercializing TULSA-PRO<sup>&#174;</sup>, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO<sup>&#174;</sup>&#160;is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient&#8217;s natural functional abilities. TULSA-PRO<sup>&#174;</sup>&#160;has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (&#8220;BPH&#8221;). TULSA-PRO<sup>&#174; </sup>is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (&#8220;FDA&#8221;).</p>  <p align="justify">Profound is also commercializing Sonalleve<sup>&#174;</sup>, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve<sup>&#174;</sup>&#160;has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve<sup>&#174;</sup>&#160;where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.</p>  <p align="justify"><strong>For further information, please contact:</strong></p>  <p align="justify">Stephen Kilmer<br >Investor Relations<br >skilmer@profoundmedical.com <br >T: 647.872.4849</p>  <p> </p><p ></p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
